BridgeBio Oncology Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
BridgeBio Oncology Therapeutics, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Clinical-stage oncology company with potentially differentiated RAS-pathway inhibitors entering combination studies in 2H 2026, supported by 2028 cash runway and recent management transition to operationalize development. BBO-8520 monotherapy showed 65% objective response rate and 68% 6-month progression-free survival in KRAS G12C non-small cell lung cancer, demonstrating clinical proof-of-concept.
What is BridgeBio Oncology Therapeutics, Inc.'s industry? BridgeBio Oncology Therapeutics, Inc. (bbotx.com) operates in Oncology Drugs. AskCyborg classifies BridgeBio Oncology Therapeutics, Inc. under Oncology Drugs in its company registry.
BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenic pathways. The company f...
Cyborg Score thesis
Clinical-stage oncology company with potentially differentiated RAS-pathway inhibitors entering combination studies in 2H 2026,...
Read the full analyst-debate transcript →Get the Latest BridgeBio Oncology Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeBridgeBio Oncology Therapeutics, Inc. Overview
Pro stress-test →BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenic pathways. The company focuses on RAS-pathway inhibitor programs and has announced encouraging preliminary safety and efficacy data across all three programs, with clinical readouts expected in the second half of 2026.
Strategic Profile
Pro stress-test →The company is entering a new phase of development as its three clinical assets enter expansions and combinations across multiple RAS-driven cancers, with leadership elevated in April 2026 to enable strategic execution. The company's cash runway extends into 2028, positioning it to advance differentiated pipeline candidates targeting patients with limited treatment options.
Competitive Landscape
Pro stress-test →BridgeBio focuses on RAS and PI3Ka-driven malignancies, competing with oncology companies developing targeted therapies against these pathways. Key competitors include companies with KRAS inhibitors, PI3K pathway inhibitors, and combination oncology programs. The space includes both established pharma and clinical-stage biotechs targeting similar patient populations and genetic drivers.
Industry Context
BridgeBio Oncology Therapeutics, Inc. operates in Oncology Drugs.
Key facts
Founded: 2018 · Headquarters: South San Francisco, US · Employees: Not disclosed · Revenue: $0 (pre-revenue clinical-stage company) · Market cap: $615M (as of June 2026)